Leflunomid Heumann

Leflunomide, the active ingredient in Leflunomid Heumann, is an immunomodulatory agent presented as a tablet for oral use. It is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis and juvenile idiopathic arthritis in adults and children as appropriate and can be used under specialist supervision.

GNH USA supplies Leflunomid Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice standards and provides reliable logistics for regulated medicines across global markets.

Leflunomide is employed as a disease-modifying antirheumatic drug to control inflammatory joint disorders.

Rheumatoid arthritis: reduces disease activity, slows joint erosion, improves functional ability, and may decrease the need for additional immunosuppressants. Psoriatic arthritis: alleviates skin lesions and joint inflammation, limits structural damage, and supports better quality of life in affected patients. Juvenile idiopathic arthritis: controls systemic inflammation, preserves joint mobility, and facilitates growth and development in pediatric patients.

Leflunomide may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea - Nausea or vomiting - Elevated liver enzymes - Rash

Serious or Rare Side Effects: - Severe liver injury or hepatitis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Teratogenic effects (birth defects)

When prescribing Leflunomid Heumann, clinicians should observe several safety measures.

Monitor liver function: obtain baseline tests and repeat periodically during therapy. Check blood pressure: measure regularly as hypertension may develop. Screen for infections: evaluate for active infections before initiating treatment. Avoid use in pregnancy: drug is teratogenic and contraindicated in pregnant women. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Leflunomid Heumann can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP1A2 inducers (e.g., rifampin) markedly reduce leflunomide exposure. - Co‑administration with other hepatotoxic agents (e.g., azole antifungals) increases risk of liver injury. - Live vaccines: heightened risk of infection; avoid during therapy.

Moderate Interactions (Monitor Closely): - Warfarin: leflunomide may enhance anticoagulant effect; monitor INR. - Methotrexate: combined use can increase hepatic toxicity. - NSAIDs: may add to liver enzyme elevations.